Compare Stocks: ELTP, CNTTF, ANRO, and PCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$24.77 -2.1%	$31.13	$4.71 ▼ $37.48	$972.05M	1.32	406,168 shs	660,689 shs
CNTTF CannTrust		$0.00	$4.35 ▼ $11.97	$1.01B	4.52	528,025 shs	1.43 million shs
ELTP Elite Pharmaceuticals	$0.23 +0.2%	$0.30	$0.22 ▼ $0.69	$244.94M	0.34	684,383 shs	1.87 million shs
PCRX Pacira BioSciences	$25.21 +0.8%	$25.28	$18.80 ▼ $27.66	$1.00B	0.25	666,593 shs	469,793 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-1.53%	-7.25%	-28.02%	+1.76%	+516.53%
CNTTF CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
ELTP Elite Pharmaceuticals	-6.12%	-8.02%	-20.27%	-33.43%	-65.85%
PCRX Pacira BioSciences	-0.16%	-2.15%	-5.52%	-1.50%	-1.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$24.77 -2.1%	$31.13	$4.71 ▼ $37.48	$972.05M	1.32	406,168 shs	660,689 shs
CNTTF CannTrust		$0.00	$4.35 ▼ $11.97	$1.01B	4.52	528,025 shs	1.43 million shs
ELTP Elite Pharmaceuticals	$0.23 +0.2%	$0.30	$0.22 ▼ $0.69	$244.94M	0.34	684,383 shs	1.87 million shs
PCRX Pacira BioSciences	$25.21 +0.8%	$25.28	$18.80 ▼ $27.66	$1.00B	0.25	666,593 shs	469,793 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-1.53%	-7.25%	-28.02%	+1.76%	+516.53%
CNTTF CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
ELTP Elite Pharmaceuticals	-6.12%	-8.02%	-20.27%	-33.43%	-65.85%
PCRX Pacira BioSciences	-0.16%	-2.15%	-5.52%	-1.50%	-1.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.64	Moderate Buy	$37.25	50.37% Upside
CNTTF CannTrust	0.00	N/A	N/A	N/A
ELTP Elite Pharmaceuticals	0.00	N/A	N/A	N/A
PCRX Pacira BioSciences	2.33	Hold	$30.14	19.57% Upside

Current Analyst Ratings Breakdown

Latest ELTP, CNTTF, ANRO, and PCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	PCRX Pacira BioSciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$32.00
9/16/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
9/9/2026	PCRX Pacira BioSciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$28.00
9/1/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/20/2026	ANRO Alto Neuroscience	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/17/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
8/17/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00
8/13/2026	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$24.00 ➝ $26.00
8/13/2026	ANRO Alto Neuroscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $37.00
8/5/2026	PCRX Pacira BioSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$24.00 ➝ $25.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
CNTTF CannTrust	$15.96M	0.00	N/A	N/A	N/A	NaN
ELTP Elite Pharmaceuticals	$148.87M	1.65	$0.03 per share	9.06	$0.09 per share	2.53
PCRX Pacira BioSciences	$726.41M	1.38	$3.88 per share	6.49	$16.11 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	11/11/2026 (Estimated)
CNTTF CannTrust	N/A	$0.07	137.18	N/A	N/A	N/A	N/A	N/A	N/A
ELTP Elite Pharmaceuticals	$44.87M	$0.04	5.69	N/A	N/A	40.19%	44.58%	29.54%	11/12/2026 (Estimated)
PCRX Pacira BioSciences	$7.03M	$0.35	72.03	10.68	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)

Latest ELTP, CNTTF, ANRO, and PCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q1 2027	ELTP Elite Pharmaceuticals	N/A	$0.01	N/A	$0.01	N/A	N/A
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A
ELTP Elite Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
CNTTF CannTrust	N/A	N/A	N/A
ELTP Elite Pharmaceuticals	0.03	3.76	2.97
PCRX Pacira BioSciences	0.54	5.04	3.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CNTTF CannTrust	0.08%
ELTP Elite Pharmaceuticals	0.01%
PCRX Pacira BioSciences	99.73%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
CNTTF CannTrust	N/A
ELTP Elite Pharmaceuticals	14.42%
PCRX Pacira BioSciences	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	68	39.24 million	34.83 million	N/A
CNTTF CannTrust	N/A	105.61 million	N/A	Not Optionable
ELTP Elite Pharmaceuticals	65	1.08 billion	921.81 million	Not Optionable
PCRX Pacira BioSciences	829	39.86 million	37.31 million	Optionable

ELTP, CNTTF, ANRO, and PCRX Headlines

Recent News About These Companies

Gyre Therapeutics (NASDAQ:GYRE) versus Pacira BioSciences (NASDAQ:PCRX) Financial Comparison

September 29 at 2:15 AM | americanbankingnews.com

240,006 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Bank of America Corp DE

September 28, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Stock Rating Raised to Strong-Buy at Wall Street Zen

September 26, 2026 | americanbankingnews.com

Pacira BioSciences (NASDAQ:PCRX) Raised to Strong-Buy at Wall Street Zen

September 26, 2026 | marketbeat.com

Oppenheimer Begins Coverage on Pacira BioSciences (NASDAQ:PCRX)

September 25, 2026 | americanbankingnews.com

Oppenheimer initiates coverage of Pacira BioSciences with outperform

September 24, 2026 | msn.com

Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target

September 23, 2026 | marketscreener.comM

Oppenheimer Initiates Coverage on Pacira BioSciences (NASDAQ:PCRX)

September 23, 2026 | marketbeat.com

Pacira BioSciences stock falls 2.35 percent to USD 24.11

September 22, 2026 | ad-hoc-news.deA

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages

September 11, 2026 | marketbeat.com

Leerink Partners initiates coverage of Pacira BioSciences at market perform

September 10, 2026 | msn.com

Pacira BioSciences (NASDAQ:PCRX) Now Covered by Leerink Partners

September 9, 2026 | marketbeat.com

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2026 | globenewswire.com

Public Employees Retirement System of Ohio Purchases New Position in Pacira BioSciences, Inc. $PCRX

September 9, 2026 | marketbeat.com

Wellington Management Group LLP Has $14.29 Million Holdings in Pacira BioSciences, Inc. $PCRX

September 8, 2026 | marketbeat.com

Legal & General Group Plc Buys Shares of 88,640 Pacira BioSciences, Inc. $PCRX

September 6, 2026 | marketbeat.com

296,880 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Bank of New York Mellon Corp

September 4, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares

August 19, 2026 | insidertrades.com

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?

August 10, 2026 | finance.yahoo.com

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

August 8, 2026 | seekingalpha.com

Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress

August 6, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTP, CNTTF, ANRO, and PCRX Company Descriptions

Alto Neuroscience NYSE:ANRO

$24.77 -0.54 (-2.13%)

Closing price 03:59 PM Eastern

Extended Trading

$24.96 +0.19 (+0.75%)

As of 04:15 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Elite Pharmaceuticals OTCMKTS:ELTP

$0.23 +0.00 (+0.18%)

As of 03:58 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Pacira BioSciences NASDAQ:PCRX

$25.21 +0.20 (+0.80%)

Closing price 04:00 PM Eastern

Extended Trading

$25.18 -0.04 (-0.14%)

As of 04:15 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELTP, CNTTF, ANRO, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELTP, CNTTF, ANRO, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELTP, CNTTF, ANRO, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTP, CNTTF, ANRO, and PCRX Company Descriptions

Alto Neuroscience NYSE:ANRO

CannTrust OTCMKTS:CNTTF

Elite Pharmaceuticals OTCMKTS:ELTP

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELTP, CNTTF, ANRO, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELTP, CNTTF, ANRO, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELTP, CNTTF, ANRO, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTP, CNTTF, ANRO, and PCRX Company Descriptions

Alto Neuroscience NYSE:ANRO

CannTrust OTCMKTS:CNTTF

Elite Pharmaceuticals OTCMKTS:ELTP

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools